AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

Clinical trial NCT06991114 · RECRUITING

Trial details

NCT number: NCT06991114
Sponsor: Artiva Biotherapeutics, Inc.
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Refractory Rheumatoid Arthritis (RA)Idiopathic Inflammatory Myopathies (IIMs)Systemic Sclerosis (SSc)Rheumatoid Arthritis (RA IIM Myositis Scleroderma Sjogren Syndrome Sjogrens Disease

Start date: 2025-07-09
Primary completion: 2028-01-01
Enrollment: 90

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.